🧾 What This Document Is

This is an 8-K filing, which companies use to announce major events to investors. This specific filing announces Phreesia's financial results for its fourth quarter and full fiscal year ended January 31, 2026. It's essentially their quarterly earnings report and includes a detailed letter to stakeholders explaining the numbers and the business's direction.

🏢 What The Company Does

👉 In simple terms, Phreesia is like a digital front desk for the healthcare industry. They provide software that helps hospitals and doctor's offices manage patient check-in, payments, appointment reminders, and patient education. Think of it as the system you interact with on a tablet or phone before you see the doctor. They make money in three main ways: charging subscriptions for their software, processing patient payments, and connecting pharmaceutical companies with doctors and patients through their network.

💰 Financial Highlights

Revenue Growth: Total revenue hit $127.1 million for the quarter, up 16% from the same time last year. For the full fiscal year, revenue was $480.6 million.

• Payment Solutions was the star, growing 45% year-over-year, largely thanks to their recent acquisition of a company called AccessOne.
• Subscription revenue grew a steady 8%.
• Network Solutions revenue grew 7%.

Profitability Milestone: The company achieved positive GAAP net income of $2.3 million for the full year. This is a major turnaround from a net loss of $58.5 million the previous year.

Key Client Metrics:

• They served an average of 4,658 healthcare clients this quarter, up 7% year-over-year.
• Revenue per client increased 8% to $27,279, showing they're getting more value from each customer.

🚀 Key Moves: The AccessOne Acquisition

In November 2025, Phreesia completed its acquisition of AccessOne for approximately $164 million. This was a big strategic move.

• Why it matters: AccessOne specializes in helping patients pay their medical bills over time, like a financing plan. This immediately boosted Phreesia's payment solutions revenue and added 80 new healthcare clients to their network. It also expanded their portfolio of patient receivables to about $419 million.

📦 Financial Position & Debt

The balance sheet changed significantly due to the acquisition.

• Assets grew to $663.8 million (from $388.4 million last year), largely from new receivables and goodwill related to AccessOne.
• Debt increased to fund the deal. They took out a $110 million short-term bridge loan, of which $90 million was still outstanding at year-end.
• Important Refinancing: After the quarter ended (on March 13, 2026), they paid off that short-term loan by securing a new $275 million, 5-year revolving credit facility. This gives them more stable, long-term funding.

💸 Cash Flow Story

This is a bright spot. Phreesia's ability to generate cash improved dramatically.

• Operating Cash Flow: They generated $78.8 million in cash from operations for the full year, compared to $32.4 million last year.
• Free Cash Flow: After accounting for capital expenditures, free cash flow was $54.4 million, up from just $8.3 million the prior year.
• Why it matters: Strong cash flow means the company can fund its growth, pay down debt, and invest without constantly needing to raise more money from investors.

🔮 What's Next: Lowered Guidance

Despite the strong quarter, the company lowered its revenue outlook for the next fiscal year (FY 2027).

• New Forecast: They now expect revenue of $510 - $520 million, down from a previous estimate of $545 - $559 million.
• The Reason: They are seeing less predictable spending commitments from some pharmaceutical companies for their network solutions. This is due to brand-specific issues and regulatory pressures, not a loss of faith in Phreesia's platform.
• The Silver Lining: They are maintaining their profit (Adjusted EBITDA) outlook of $125 - $135 million, meaning they plan to cut costs to protect profits despite lower sales. They are also focusing on using AI to improve efficiency.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Reached key profitability and cash flow milestones.
• Successful integration of the AccessOne acquisition, which is already boosting revenue.
• Growing client base and revenue per client.
• Proven operating leverage (expenses growing slower than revenue).

⚠️ Risks:

• Dependence on Pharma Spending: Their Network Solutions revenue is volatile and tied to the marketing budgets of pharmaceutical companies, which can be unpredictable.
• Integration Risk: Successfully merging AccessOne into their core business is an ongoing challenge.
• Competition & Technology: The healthcare tech space is competitive, and rapid advances in AI could be a threat or an opportunity they must navigate.
• Economic/Regulatory Factors: Broader healthcare policy changes and economic conditions can impact their clients' spending.

🧠 The Analogy

Phreesia is like a company that built the essential digital kiosks and payment terminals for every airport in the country. They make steady money from subscriptions (charging the airports for the kiosks) and transaction fees (processing payments). Then, they acquired a company that offers travelers a "buy now, pay later" plan for expensive trips, adding a new, high-margin revenue stream. Their recent challenge is that some of the airlines (their pharma clients) are cutting back on their advertising spend inside the terminals, which hurts one part of the business, but the core kiosk and payment operations are now profitable and generating lots of cash.

📇 Key Contacts & People

• Chaim Indig: Chief Executive Officer and Co-Founder
• Balaji Gandhi: Investor Relations Contact ([email protected], (929) 506-4950)
• Nicole Gist: Media Contact ([email protected], (407) 760-6274)

🧩 Final Takeaway

Phreesia achieved a major financial turning point in FY 2026, becoming profitable and cash-flow positive, largely fueled by the strategic AccessOne acquisition. However, they face near-term revenue headwinds from volatile pharmaceutical client spending, forcing them to lower their sales outlook while leaning on cost controls to maintain profitability targets.